Fujirebio Europe launches Lumipulse® G Progesterone-N, a biomarker for high-risk pregnancy monitoring and a valuable aid in detection and management of various causes of infertility

Product news

Gent, Belgium: October 26, 2015 - Fujirebio Europe announces the addition of the Lumipulse G Progesterone-N assay to the existing fertility test portfolio for use on the CLEIA-based LUMIPULSE G600II and the LUMIPULSE G1200 immunoassay systems. Progesterone is a steroid hormone that is synthesized in the gonads and the adrenal glands; measurement of progesterone can be used as one of the indicators of luteal function  in the investigation of infertility and also placental function during pregnancy.

“The main role of Progesterone is to help prepare a woman's body for pregnancy.” said Christiaan De Wilde, CEO at Fujirebio Europe. “The Lumipulse G Progesterone-N is already widely used on the Japanese market and has shown to be a valuable aid for clinicians in the detection and monitoring of various causes of infertility. The test is often used in combination with other biomarkers such as FSH, LH, hCG and thyroid tests, which are already available for automated testing on our LUMIPULSE G systems.”

Please contact your local sales representative for the availability of these products in your country.

About Fujirebio
Fujirebio is a leading international healthcare company with a strong focus on high quality in vitro diagnostics (IVD) testing solutions. Founded more than 60 years ago in Japan, the company is today recognized as the world-wide market leader in oncology for both routine and novel markers and has a strong reputation in Japan in infectious disease testing in hospitals, clinical labs and blood banks. Over the last 20 years Fujirebio has been committed to bringing solid and successful automated immunoassay testing solutions and state of the art chemiluminescent assay products to the market. Under the name Innogenetics (now Fujirebio Europe) the company has also been pioneering the field of molecular diagnostics and multiparameter testing. The company is today one of the world leaders in strip-based diagnostics solutions.

The product lines range from specialized manual testing to fully automated routine testing and they cover disease fields such as infectious, oncology, genetic testing, thyroid, fertility, tissue typing, neurodegeneration and bone.

Fujirebio is a subsidiary of Japan-based Miraca Holdings (listed in the Tokyo Stock Exchange - MRCHF) and counts more than 1.100 employees working in Asia, Europe and America, including subsidiaries. For more information about Fujirebio please visit www.fujirebio.com/english or www.fujirebio-europe.com.